VOR - Gunggung utang perusahaan vorbio.com

VOR (vorbio.com) - tandha merek perusahaan

The linear price action on the chart for Vor Biopharma Inc. (VOR) reflects a debt load of 0.00. The business focuses on developing treatments for blood tumors, although political fragmentation among nations hinders genetic exchange and slows global testing. Meanwhile, the U.S. development base for cellular methods remains stable, as the absence of trade restrictions ensures process predictability for the company.

Vor Bio Inc. - Utang perusahaan VOR (periode 04.07.2022 - 28.10.2026)

Rincian metrik lan analitis perusahaan Vor Biopharma (VOR)

- rega lan prakiraan konsensus rega:
Kurs saham Vor Bio Inc.|VOR - Prakiraan konsensus analis
- data kapitalisasi pasar:
Biji pasar Vor Bio|VOR - Nilai Perusahaan
- data kapitalisasi buku:
Nilai Aset Bersih saben Saham Vor Biopharma|VOR - Nilai Buku Perusahaan|Nilai Pasar marang Nilai Buku vorbio.com|VOR - Gunggung Aset Perusahaan
- data utang lan likuiditas:
Rasio Kabeh Utang marang Dana Pribadi Vor Biopharma Inc.|VOR - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Vor Biopharma, Inc.|VOR - Utang perusahaan|Rasio utang marang kapitalisasi buku Vor Bio|VOR - Utang jangka dawa perusahaan|Utang jangka cendhak Vor Biopharma
Analisis fundamental perusahaan:Vor Bio Inc. VOR
Produk mawa merek Vor Biopharma, Inc.

Comparative asset analysis requires a precise determination of leverage to assess business resilience. This metric aggregates all short-term and long-term liabilities, measuring the total volume of borrowed capital. For Vor Biopharma Inc. (VOR), financial stability is determined by the success of clinical trials rather than market cycles. It is critical for investors to correlate borrowing rates with progress in cellular engineering. The aggregate creditor burden reflects the balance between innovation development and liquidity risk.

Analisis pesaing Vor Biopharma Inc.

Utang agregat perusahaan TG Pharma (TGTX)|Arcellx - Gunggung utang perusahaan|Gunggung utang perusahaan discmedicine.com IRON|SNDX (Syndax Pharmaceuticals, Inc.) - Gunggung utang perusahaan|KURA: Utang kumulatif perusahaan|Utang perusahaan ADC Therapeutics Corp ADCT|Kewajiban utang agregat Foghorn Therapeutics Inc.|NKTX - Gunggung utang perusahaan|Kewajiban utang agregat Coeptis|Gunggung utang perusahaan Actinium Pharmaceuticals, Inc. (ATNM)|Utang perusahaan ESLA (Estrella Immunopharma Inc)|Utang perusahaan CASI Pharmaceuticals, Inc. CASI|Marker Therapeutics Inc - Utang perusahaan|INAB (IN8bio, Inc.) - Utang perusahaan|ERNA: Utang kumulatif perusahaan|Utang perusahaan GTBP|Aptose Biosciences (APTO) - Utang kumulatif perusahaan|Gunggung utang perusahaan Bio-Path (BPTH)|Utang agregat perusahaan MEI Pharma Corporation (MEIP)|Gunggung utang perusahaan Vincerx Pharma, Inc. (VINC)